Rexulti (Brexpiprazole), is an atypical antipsychotic that was jointly developed by pharmaceutical companies Otsuka and Lundbeck. In 2015, the FDA approved Rexulti for the treatment of schizophrenia and major depressive disorder (as an adjunct). Rexulti functions as a “serotonin-dopamine activity modulator” (SDAM) and is intended to be a superior successor to the antipsychotic Abilify (Aripiprazole) …
Trintellix (Vortioxetine hydrobromide), formerly sold under the name Brintellix, is an antidepressant that was jointly developed by the pharmaceutical companies Lundbeck and Takeda. In 2013, Trintellix received FDA approval for the treatment of major depressive disorder in the United States. Trintellix is classified as a “serotonin modulator and stimulator” in that it functions as an …
ZzzQuil is an over-the-counter medication utilized most frequently to enhance sleep quality among individuals with allergies or the “common cold.” However, because ZzzQuil is a potent sleep aid, individuals without health problems sometimes use the medication to help manage insomnia. On occasion, ZzzQuil is even administered for the treatment of motion sickness and extrapyramidal symptoms …
Rexulti (Brexpiprazole), is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia and major depressive disorder (as an adjunct). The drug was engineered via collaboration between pharmaceutical companies Otsuka and Lundbeck and is considered the successor to Abilify (aripiprazole), a formerly top-selling antipsychotic medication with an expired patent. Although Rexulti is marketed …
Vyvanse (Lisdexamfetamine) is a prodrug comprised of the amino acid L-lysine coupled with dextroamphetamine, hence its chemical name “lis-dexamfetamine.” As a prodrug, Vyvanse is inactive until ingested and enzymatically metabolized into l-lysine (an amino acid) and dextroamphetamine (a psychostimulant), the latter of which has been deemed effective for the treatment of ADHD and binge eating …
Xanax (alprazolam) is a drug of the benzodiazepine class originally developed by Upjohn, a Michigan-based pharmaceutical company (now a subsidiary of Pfizer). In the United States, Xanax first received FDA approval for the treatment of panic disorder and hit the market as a prescription medication in 1981. It eventually received subsequent FDA approval for the …
ZzzQuil is an over-the-counter (OTC) sleep aid manufactured by Vicks (a subsidiary of Proctor & Gamble) that initially hit the market in 2012. When administered on an “as-needed” basis, ZzzQuil is thought to alleviate occasional bouts of insomnia and other sleep disturbances with minimal risk of abuse, addiction, and/or dependence – as compared to pharmaceutical …